{"id":2222,"date":"2025-02-04T12:00:49","date_gmt":"2025-02-04T12:00:49","guid":{"rendered":"https:\/\/onltherapeutics.com\/test\/?p=2222"},"modified":"2026-01-05T21:01:38","modified_gmt":"2026-01-05T21:01:38","slug":"onl-therapeutics-announces-multiple-presentations-at-leading-ophthalmology-meetings","status":"publish","type":"post","link":"https:\/\/onltherapeutics.com\/test\/2025\/02\/04\/onl-therapeutics-announces-multiple-presentations-at-leading-ophthalmology-meetings\/","title":{"rendered":"ONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\" style=\"padding-right:0px;padding-left:0px;font-style:normal;font-weight:700\">ONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings<\/h3>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>ANN ARBOR, Mich., Feb. 4, 2025<\/strong> \u2013 <a href=\"https:\/\/onltherapeutics.com\/test\/\">ONL Therapeutics, Inc.<\/a>, a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will present clinical data and scientific research at the following first quarter meetings:<\/p>\n\n\n\n<p><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">48th Annual Meeting of the Macula Society, February 12-15, 2025, at the Sunseeker Resort in Charlotte Harbor, Florida<\/li>\n\n\n\n<li class=\"has-medium-font-size\">Glaucoma Innovation Summit at the American Glaucoma Society (AGS) 2025 Annual Meeting, February 26 &#8211; March 2, 2025, at the Omni Shoreham Hotel in Washington, D.C.<\/li>\n\n\n\n<li class=\"has-medium-font-size\">9th Military Vision Symposium on Novel Technology and Vision Restoration hosted by Harvard Medical School Department of Ophthalmology and Mass Eye and Ear, February 27-28, 2025, at the Starr Center and Wyndham Boston Beacon Hill Hotel in Boston, Massachusetts<\/li>\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>Details of the Macula Society Meeting presentation<\/strong>:<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:13.33%\">\n<p><strong>Title:<\/strong><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p>Fas Inhibition with ONL1204 Ophthalmic Solution for the Treatment of Geographic Atrophy: AI Analysis of Images from a Phase 1b Study<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:13.33%\">\n<p><strong>Presenter:<\/strong><span style=\"font-size: medium; white-space-collapse: collapse;\"><\/span><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p>Baruch D. Kuppermann, M.D., Ph.D.<br>Chair, Department of Ophthalmology<br>Director, Gavin Herbert Eye Institute<br>University of California, Irvine<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:13.33%\">\n<p><strong>Time\/Date:<\/strong><span style=\"font-size: medium; white-space-collapse: collapse;\"><\/span><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p>2:30 p.m. ET on Friday, February 14, 2025<\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>Details of the Glaucoma Innovation Summit at AGS 2025 presentation<\/strong>:<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:13.33%\">\n<p><strong>Title:<\/strong><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p>Fas Inhibition with ONL1204 for the Treatment of Open-Angle Glaucoma: Results from a Phase 1b Study<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:13.33%\">\n<p><strong>Presenter:<\/strong><span style=\"font-size: medium; white-space-collapse: collapse;\"><\/span><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p>Jeffrey Goldberg, M.D., Ph.D.<br>Professor and Chair of Ophthalmology<br>Byers Eye Institute at Stanford University<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:13.33%\">\n<p><strong>Time\/Date:<\/strong><span style=\"font-size: medium; white-space-collapse: collapse;\"><\/span><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p>6:00 p.m. ET on Thursday, February 27, 2025<\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>Details of the Military Vision Symposium keynote lecture<\/strong>:<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:13.33%\">\n<p><strong>Title:<\/strong><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p>Photoreceptor Cell Death: Life Hanging in the Balance<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:13.33%\">\n<p><strong>Presenter:<\/strong><span style=\"font-size: medium; white-space-collapse: collapse;\"><\/span><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p>David N. Zacks, M.D., Ph.D.<br>Professor, Ophthalmology and Visual Sciences, University of Michigan<br>Chief Scientific Officer, ONL Therapeutics<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:13.33%\">\n<p><strong>Time\/Date:<\/strong><span style=\"font-size: medium; white-space-collapse: collapse;\"><\/span><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p>4:25 p.m. \u2013 4:55 p.m. ET on Thursday, February 27, 2025<\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>About ONL1204 Ophthalmic Solution<\/strong><br>ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions. Death of these retinal cells, through both direct and inflammatory signaling pathways, is the root cause of vision loss and the leading cause of blindness. The company\u2019s later stage clinical development program for ONL1204 includes a Phase 2 study for the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06659445\" target=\"_blank\" rel=\"noreferrer noopener\">NCT06659445<\/a>) and a completed Phase 2 study in the U.S. for the treatment of macula-off retinal detachment (RD) (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05730218\" target=\"_blank\" rel=\"noreferrer noopener\">NCT05730218<\/a>), a condition for which the compound has been granted orphan drug designation by the United States Food and Drug Administration (FDA). The company has also completed a Phase 1b clinical trial in patients with GA associated with AMD (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04744662\" target=\"_blank\" rel=\"noreferrer noopener\">NCT04744662<\/a>), a Phase 1b clinical trial in patients with progressing open-angle glaucoma (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05160805\" target=\"_blank\" rel=\"noreferrer noopener\">NCT05160805<\/a>) and a Phase1 clinical trial in macula-off RD patients at sites in Australia and New Zealand (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03780972\" target=\"_blank\" rel=\"noreferrer noopener\">NCT03780972<\/a>).<\/p>\n\n\n\n<p><strong>About ONL Therapeutics<\/strong><br>ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision.<\/p>\n\n\n\n<p>For more information about ONL Therapeutics, please visit <a href=\"https:\/\/onltherapeutics.com\/test\/\">www.onltherapeutics.com<\/a>.<\/p>\n\n\n\n<p><strong>Company Contact<\/strong>:<br>Linda Kemnitz<br>ONL Therapeutics, Inc.<br><a href=\"mailto:lkemnitz@onltherapeutics.com\" target=\"_blank\" rel=\"noreferrer noopener\">lkemnitz@onltherapeutics.com<\/a><\/p>\n\n\n\n<p><\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2025\/01\/ONL-PR-2025.0204-Ophthalmology-Meeting-Presentations.pdf\" style=\"border-radius:36px\" target=\"_blank\" rel=\"noreferrer noopener\">Download Press Release<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings ANN ARBOR, Mich., Feb. 4, 2025 \u2013 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will present clinical data and scientific research at the following first quarter meetings: Details of [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"blank","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[5,6],"tags":[],"class_list":["post-2222","post","type-post","status-publish","format-standard","hentry","category-news","category-onl-therapeutics-news"],"featured_image_urls_v2":{"full":"","thumbnail":"","medium":"","medium_large":"","large":"","1536x1536":"","2048x2048":"","gform-image-choice-sm":"","gform-image-choice-md":"","gform-image-choice-lg":""},"post_excerpt_stackable_v2":"<p>ONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings ANN ARBOR, Mich., Feb. 4, 2025 \u2013 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will present clinical data and scientific research at the following first quarter meetings: 48th Annual Meeting of the Macula Society, February 12-15, 2025, at the Sunseeker Resort in Charlotte Harbor, Florida Glaucoma Innovation Summit at the American Glaucoma Society (AGS) 2025 Annual Meeting, February 26 &#8211; March 2, 2025, at the Omni Shoreham Hotel in Washington, D.C. 9th Military Vision&hellip;<\/p>\n","category_list_v2":"<a href=\"https:\/\/onltherapeutics.com\/test\/category\/news\/\" rel=\"category tag\">News<\/a>, <a href=\"https:\/\/onltherapeutics.com\/test\/category\/onl-therapeutics-news\/\" rel=\"category tag\">News Items<\/a>","author_info_v2":{"name":"ONL Therapeutics","url":"https:\/\/onltherapeutics.com\/test\/author\/onl-therapeutics\/"},"comments_num_v2":"0 comments","_links":{"self":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/posts\/2222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/comments?post=2222"}],"version-history":[{"count":14,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/posts\/2222\/revisions"}],"predecessor-version":[{"id":2244,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/posts\/2222\/revisions\/2244"}],"wp:attachment":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/media?parent=2222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/categories?post=2222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/tags?post=2222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}